Scholars Central

OtherPublished 23 Jul 2016

Outcome measures in amyotrophic lateral sclerosis clinical trials

Authors: Sabrina Paganoni, Merit Cudkowicz, James D Berry

Clinical Investigation

Volume 4 · Issue 7 · Pages 605–618

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with an average survival of 3–5 years. While therapies for ALS remain limited, basic and translational ALS research has been host to numerous influential discoveries in recent years. These discoveries have led to a large pipeline of potential therapies that await testing in clinical trials. Until recently, ALS clinical trials have relied on a limited cadre of ‘traditional’ outcome measures, including survival and measures of function. These measures have proven useful, although imperfect, in Phase III ALS trials. However, their utility in early-phase ALS trials is limited. For these early trials, outcome measures focused on target engagement or biological pathway analysis might improve trial outcomes and better support the drug development process.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Investigation.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Sabrina Paganoni”
  • BylineArticles whose byline prints “Merit Cudkowicz”
  • BylineArticles whose byline prints “James D Berry”